Formulating for the Future of Transplant Patient Therapy


Veloxis is a specialty pharmaceutical company committed to improving the lives of transplant patients. Our unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs.

Veloxis Pharmaceuticals A/S is headquartered Copenhagen, DK and operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.

Veloxis is committed to patient access and financial support for kidney transplant patients. Learn more about our prescription cost savings programs, click here arrow

May 15, 2018

Conference call at 4:00 pm CEST

Please join the event conference 5-10 minutes prior to the start time. 

Confirmation Code: 8366822

Denmark: +45 35 15 80 49 

United Kingdom: +44 (0)330 336 9105 

United States: +1 646-828-8156